Poractant alfa versus beractant for respiratory distress syndrome in preterm infants: A retrospective cohort study

Journal of Paediatrics and Child Health

Volumn 49, Issue 10, 2013, Pages 839-844

  Paul, Saritha ^a,b,c   Rao, Shripada ^a,b,c   Kohan, Rolland ^a,c   McMichael, Judy ^a,b   French, Noel ^a,c   Zhang, Guicheng ^b   Simmer, Karen ^a  

^a KING EDWARD MEMORIAL HOSPITAL   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

chronic lung disease; premature infant; pulmonary surfactant; respiratory distress syndrome

Indexed keywords

BERACTANT; PORACTANT; BIOLOGICAL PRODUCT; LUNG SURFACTANT; PHOSPHOLIPID;

ARTICLE; CHILDHOOD MORTALITY; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN INTENSIVE CARE; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; TREATMENT OUTCOME; COMPARATIVE STUDY; MORTALITY; NEWBORN; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RETROSPECTIVE STUDY;

BIOLOGICAL PRODUCTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84886102326     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/jpc.12300     Document Type: Article

References (25)

1. Seger N, Soll R,. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst. Rev. 2009; (2): CD007836.
2. Soll RF, Blanco F,. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst. Rev. 2001; (2): CD000144.
3. van Kaam AH, De Jaegere AP, Borensztajn D, Rimensberger PC,. Surfactant replacement therapy in preterm infants: a European survey. Neonatology 2011; 100: 71-77.
4. Halliday HL,. History of surfactant from 1980. Biol. Neonate 2005; 87: 317-322.
5. Parry G, Tucker J, Tarnow-Mordi W,. CRIB II: an update of the clinical risk index for babies score. Lancet 2003; 361: 1789-1791.
6. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116: 1353-1360.
7. Jobe AH, Bancalari E,. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 2001; 163: 1723-1729.
8. Huntley M, ed. The Griffiths Mental Development Scales from birth to 2 years manual. 1996 revision: association for research in Infant and Child Development. 1996.
9. Bayley N,. Bayley Scales of Infant and Toddler Development. San Antonio, TX: The Psychological Corporation, 2006.
10. Ramanathan R, Bhatia JJ, Sekar K, Ernst FR,. Mortality in preterm infants with respiratory distress syndrome treated with poractant alfa, calfactant or beractant: a retrospective study. J. Perinatol. 2013; 33: 119-125.
11. Singh N, Hawley KL, Viswanathan K,. Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: systematic review and meta-analysis. Pediatrics 2011; 128: e1588-1595.
12. Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C,. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur. J. Pediatr. 2003; 162: 476-480.
13. Fujii AM, Patel SM, Allen R, Doros G, Guo CY, Testa S,. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J. Perinatol. 2010; 30: 665-670.
14. Gharehbaghi MM, Sakha SH, Ghojazadeh M, Firoozi F,. Complications among premature neonates treated with beractant and poractant alfa. Indian J. Pediatr. 2010; 77: 751-754.
15. Malloy CA, Nicoski P, Muraskas JK,. A randomized trial comparing beractant and poractant alfa treatment in neonatal respiratory distress syndrome. Acta Paediatr. 2005; 94: 779-784.
16. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K,. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am. J. Perinatol. 2004; 21: 109-119.
17. Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch. Dis. Child. Fetal Neonatal Ed. 1995; 72: F8-13.
18. Dizdar EA, Sari FN, Aydemir C, et al. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome. Am. J. Perinatol. 2012; 29: 95-100.
19. Borzak S, Ridker PM,. Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann. Intern. Med. 1995; 123: 873-877.
20. Flather MD, Farkouh ME, Pogue JM, Yusuf S,. Strengths and limitations of meta-analysis: larger studies may be more reliable. Control. Clin. Trials 1997; 18: 568-579. discussion 661-566.
21. Hennekens CH, Demets D,. The need for large-scale randomized evidence without undue emphasis on small trials, meta-analyses, or subgroup analyses. JAMA 2009; 302: 2361-2362.
22. Sweet DG, Carnielli V, Greisen G, et al. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update. Neonatology 2010; 97: 402-417.
23. Engle WA,. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121: 419-432.
24. Assmann SF, Pocock SJ, Enos LE, Kasten LE,. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 1064-1069.
25. Fletcher J,. Subgroup analyses: how to avoid being misled. BMJ 2007; 335: 96-97.